Immunotherapy drug may delay cancer's return after surgery
NCT ID NCT02769520
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests whether the immunotherapy drug pembrolizumab can help people with head and neck cancer that has come back after initial treatment. After surgery to remove the recurrent tumor, participants receive pembrolizumab to see if it extends the time before the cancer returns again. The trial enrolled 27 adults and tracks how long they remain cancer-free and any side effects.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SQUAMOUS CELL CARCINOMA OF THE HEAD AND NECK are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
UCSD Moores Cancer Center
La Jolla, California, 92093, United States
-
University of California Los Angeles
Torrance, California, 90505, United States
-
University of California San Francisco
San Francisco, California, 94115, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can Pre-Surgery immunotherapy prime the immune system to fight head and neck cancer?
- Can a new drug boost the power of chemoradiation against head and neck cancer?
- Experimental antibody combo aims to boost immune attack on head and neck tumors
- Scientists hunt for blood markers to unmask hidden aggressive tumors
- Liver damage study in head and neck cancer abandoned after just 2 patients
- New antibody drug takes aim at Hard-to-Treat cancers